Forte Biosciences, Inc. - Common Stock (FBRX)

Competitors to Forte Biosciences, Inc. - Common Stock (FBRX)

Amgen Inc. 

Amgen Inc. is a leading biotechnology company that, like Forte Biosciences, focuses on developing therapies for serious medical conditions. Amgen has a broad portfolio of products approved for various indications, including autoimmune diseases, that presents significant competition to Forte's offerings. While both companies target similar patient populations, Amgen's extensive experience, larger resource base, and established market presence give it a competitive advantage over the smaller Forte Biosciences.

Convatec Group plc

Convatec specializes in advanced medical products for wound and skin care, thereby competing with Forte Biosciences in the skin health sector. While both companies focus on improving skin conditions, Convatec's extensive development and production capabilities in wound care provide it with a significant competitive advantage in terms of product variety and distribution networks. Forte, with a narrower focus, may find it challenging to compete broadly at similar scales.

Eli Lilly and Company 

Eli Lilly is a well-established pharmaceutical company with a large repertoire of biologics and medications for chronic diseases, including dermatological indications. Forte Biosciences competes by focusing specifically on innovative treatments for skin-related conditions, but Eli Lilly's significant investment in R&D, market reach, and established relationships with healthcare providers provide it with an advantage in brand recognition and distribution that can overshadow Forte's more niche offerings.

Galderma

Galderma is a global dermatological company focused on a variety of skin health products, including treatments for acne and psoriasis, very similar to the areas Forte Biosciences targets. Galderma's extensive range of products and established market presence in dermatology provide a strong competitive edge over Forte. While Forte may innovate with specific product developments, the size and resource implications of Galderma give it an advantage in the dermatology market.

Incyte Corporation 

Incyte is a biopharmaceutical company that specializes in developing innovative therapies for dermatological and oncology indications, directly competing with Forte Biosciences in the field of skin diseases. Both companies are invested in the development of specialty drugs, but Incyte's diverse pipeline and established market presence in other therapeutic areas provide it with a competitive advantage in leveraging resources and reaching broader markets. Forte may maintain an edge in specific niche therapies but overall competes as a smaller player.